Get the Stockscreener App
174.41
2.08%
3.56
After Hours:
165.69
-8.72
-5.00%
Krystal Biotech Inc stock is traded at $174.41, with a volume of 242.26K.
It is up +2.08% in the last 24 hours and down -1.52% over the past month.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
See More
Previous Close:
$170.85
Open:
$172.48
24h Volume:
242.26K
Relative Volume:
1.13
Market Cap:
$5.02B
Revenue:
-
Net Income/Loss:
$105.94M
P/E Ratio:
-118.65
EPS:
-1.47
Net Cash Flow:
$-22.76M
1W Performance:
-1.02%
1M Performance:
-1.52%
6M Performance:
+8.26%
1Y Performance:
+42.78%
1-Day Range:
$170.65
$175.96
1-Week Range:
$163.66
$176.49
52-Week Range:
$93.95
$219.34
Krystal Biotech Inc Stock (KRYS) Company Profile
Name
Krystal Biotech Inc
Sector
Industry
Phone
(412) 586-5830
Address
2100 WHARTON STREET, PITTSBURGH, PA
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-23 | Initiated | Goldman | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-12-23 | Initiated | Citigroup | Buy |
| Sep-07-23 | Initiated | Berenberg | Buy |
| Apr-18-23 | Initiated | Stifel | Buy |
| Feb-28-23 | Upgrade | Goldman | Neutral → Buy |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-18-22 | Initiated | BofA Securities | Buy |
| Jul-20-21 | Upgrade | Goldman | Neutral → Buy |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Jun-04-20 | Initiated | Evercore ISI | Outperform |
| Sep-24-19 | Initiated | Goldman | Neutral |
| Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-24-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-24-19 | Reiterated | H.C. Wainwright | Buy |
| May-30-19 | Initiated | Guggenheim | Buy |
| Sep-11-18 | Initiated | Cantor Fitzgerald | Overweight |
View All
Krystal Biotech Inc Stock (KRYS) Latest News
Krystal Q3 Earnings and Sales Top Estimates, Vyjuvek Gains Traction - Yahoo Finance
Krystal Biotech (NASDAQ:KRYS) Price Target Raised to $206.00 at Citigroup - MarketBeat
Krystal Biotech (NASDAQ:KRYS) Earns "Buy" Rating from HC Wainwright - MarketBeat
Krystal Biotech (NASDAQ:KRYS) Announces Earnings Results, Beats Expectations By $0.07 EPS - MarketBeat
Krystal Biotech, Inc. (NASDAQ:KRYS) Q3 2024 Earnings Call Transcript - Insider Monkey
Krystal Biotech Third Quarter 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Krystal Biotech Inc (KRYS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Krystal Biotech Faces Challenges in Scaling VYJUVEK Production Amid Regulatory Hurdles - TipRanks
Earnings call: Krystal Biotech reports robust Q3 2024 results By Investing.com - Investing.com Nigeria
Krystal Biotech Reports Strong Q3 2024 Performance - TipRanks
Krystal Biotech (NASDAQ:KRYS) Shares Gap DownHere's Why - MarketBeat
Krystal Biotech, Inc. (KRYS) Beats Q3 Earnings and Revenue Estimates - Yahoo Finance
Krystal Biotech earnings missed by $0.08, revenue topped estimates - Investing.com UK
Krystal Biotech Announces Third Quarter 2024 Financial Results and Provides Business Updates - The Manila Times
Krystal Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Are Options Traders Betting on a Big Move in Krystal Biotech (KRYS) Stock? - MSN
Where are the Opportunities in (KRYS) - Stock Traders Daily
Earnings To Watch: Krystal Biotech Inc (KRYS) Reports Q3 2024 Re - GuruFocus.com
Earnings To Watch: Krystal Biotech Inc (KRYS) Reports Q3 2024 Results - Yahoo Finance
Krystal Biotech (KRYS) Set to Announce Quarterly Earnings on Monday - MarketBeat
Krystal Biotech, Inc. (KRYS) to Report Q3 Results: Wall Street Expects Earnings Growth - MSN
Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024 - The Manila Times
Hennion & Walsh Asset Management Inc. Cuts Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
(KRYS) Proactive Strategies - Stock Traders Daily
Everence Capital Management Inc. Invests $557,000 in Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK(TM) (beremagene geperpavec-svdt) for the Treatment of Dystrophic Epidermolysis Bullosa - InvestorsObserver
All You Need to Know About Krystal Biotech (KRYS) Rating Upgrade to Buy - MSN
Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
State Street Corp's Strategic Acquisition in Krystal Biotech Inc - Yahoo Finance
Krystal Biotech: Q4 Catalysts Expected With VYJUVEK Revenue Growth Pressing On - Seeking Alpha
Exploring Three High Growth Tech Stocks in the United States - Simply Wall St
Shaker Investments LLC OH Acquires Shares of 2,920 Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
When (KRYS) Moves Investors should Listen - Stock Traders Daily
US Growth Stocks With High Insider Ownership - Simply Wall St
Bank of Montreal Can Purchases Shares of 2,936 Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Exelixis Gains 20.7% in Three Months: Is This the Right Time to Buy? - Benzinga
Handelsbanken Fonder AB Has $17.24 Million Stake in Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Krystal Biotech (KRYS) Stock Price, News & Analysis - MarketBeat
Krystal Biotech And 6 Other Stocks Have High Sales Growth And An Above 3% Return on Equity - Via News Agency
Teachers Retirement System of The State of Kentucky Takes $555,000 Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Krystal Biotech, Inc. : Will it go even higher? - Marketscreener.com
How the (KRYS) price action is used to our Advantage - Stock Traders Daily
Krystal Biotech shares reiterate buy rating, price target on strong fundamentals - Investing.com India
Vanguard Personalized Indexing Management LLC Takes Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Bought by Sei Investments Co. - MarketBeat
Driehaus Capital Management LLC Buys 8,547 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Amalgamated Bank Has $1.39 Million Stake in Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Krystal Biotech (NASDAQ: KRYS)Related Research - Intelligent Investor
54,656 Shares in Krystal Biotech, Inc. (NASDAQ:KRYS) Acquired by Public Sector Pension Investment Board - MarketBeat
Top investors say Krystal Biotech Inc (KRYS) ticks everything they need - SETE News
Avoro Capital Advisors LLC Reduces Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Krystal Biotech Inc Stock (KRYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):